Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is “compelled” by the already developing efficacy signal/trends at 24-months where uniQure got alignment with the FDA and continuing RMAT plus CBER tailwinds, which it thinks make the set up “bullish” as uniQure moves towards filing a BLA, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Biotech Alert: Searches spiking for these stocks today
- uniQure price target raised to $44 from $26 at Leerink
- uniQure price target raised to $20 from $14 at RBC Capital
- Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s
- uniQure upgraded to Overweight from Equal Weight at Wells Fargo